Recent studies suggest that Panobinostat can inhibit EGFR expression in EGFR-mutant lung cancer cells, and the combination of EGFR-TKI drugs like Erlotinib with Panobinostat may synergistically suppress lung cancer cell proliferation (44). The gene discussed is EGFR; the disease is lung cancer.